The EMA Qualification of Novel Methodologies (QoNM) provides a voluntary, scientific pathway to support development, evaluation and regulatory endorsement of innovative methodologies in specific contexts of use.
In this guidance, the term ‘methodologies’ refers to approaches allowing to generate evidence that supports regulatory benefit-risk assessment and decision making related to medicinal products throughout their lifecycle (development, use or monitoring of medicinal products pre- or postauthorisation)